Blueprint Medicines Corp Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2018 to Q1 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Blueprint Medicines Corp quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2018 to Q1 2025.
- Blueprint Medicines Corp Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2025 was $1.29M, a 98.6% decline year-over-year.
- Blueprint Medicines Corp Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2025 was -$154M, a 46.5% increase year-over-year.
- Blueprint Medicines Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was -$65.9M, a 87% increase from 2023.
- Blueprint Medicines Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$506M, a 8.38% increase from 2022.
- Blueprint Medicines Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$552M, a 13.9% increase from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)